XML 66 R56.htm IDEA: XBRL DOCUMENT v3.23.2
Note 12 - Segment Information - Operating Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Revenues $ 50,645 $ 50,453
Gross profit (loss) 31,183 31,341
Operating expenses 31,847 35,935
Operating (loss) (664) (4,594)
Nonoperating expense, net (273) (818)
(Loss) before income taxes (937) (5,412)
Operating Segments [Member]    
Gross profit (loss) 31,183 31,358
Operating expenses 31,847 35,935
Operating (loss) (664) (4,594)
Nonoperating expense, net 273 818
(Loss) before income taxes (937) (5,412)
Operating Segments [Member] | Sterilization and Disinfection Control [Member]    
Revenues [1] 15,927 14,774
Gross profit (loss) 11,591 10,768
Operating Segments [Member] | Clinical Genomics [Member]    
Revenues [1] 13,369 14,505
Gross profit (loss) 6,728 7,849
Operating Segments [Member] | Biopharmaceutical Development [Member]    
Revenues [1] 9,889 10,967
Gross profit (loss) 6,433 7,077
Operating Segments [Member] | Calibration Solutions [Member]    
Revenues [1],[2] 11,460 10,207
Gross profit (loss) 6,431 5,664
Corporate, Non-Segment [Member]    
Revenues [1],[3] $ 0 $ (17)
[1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.
[2] Revenues in the Clinical Genomics division represent transactions subsequent to the Agena Acquisition on October 20, 2021.
[3] Unallocated corporate expenses and other business activities are reported within Corporate and Other.